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Background: Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-
wide methylation status and play an important role in maintaining genomic stability and gene expression.
To derive insight into the association between genome-wide methylation status and tetralogy of fallot (TOF),
we compared the methylation status of LINE-1 element between TOF patients and controls. The methylation
of the NKX 2–5, HAND 1, and TBX 20 promoter regions was also evaluated.
Methods: Genomic DNA from right ventricular tissue samples was obtained from 32 patients with TOF and 15
control subjects. Sequenom MassARRAY platform was performed to examine the methylation levels of LINE-1, NKX2-
5, HAND1 and TBX20. Mann–Whitney U test was used to compare differences in methylation levels between two
groups.
Results: The methylation level of LINE-1 was significantly lower in patients with TOF, with a median of 57.95%
(interquartile range [IQR]: 56.10%–60.04%), as opposed to 59.70% in controls (IQR: 59.00%–61.30%; P= 0.0021).
The highest LINE-1 methylation level was 61.3%. The risk of TOF increased in subjects with the lowest methylation
levels (less than or equal to 59.0%; OR = 14.7, 95% CI: 1.8–117.7, P= 0.014) and in those with medium methylation
levels (59.0%–61.3%; OR = 2.0, 95% CI: 0.3–14.2, P= 0.65). An ROC curve analysis showed a relatively high accuracy
of using the LINE-1 methylation level in predicting the presence of TOF (AUC= 0.78, 95% CI: 0.65–0.91; P= 0.002).
The association of the LINE-1 methylation level with TOF was only observed in males (P= 0.006) and not in females
(P= 0.25). Neither age nor gender was found to be associated with the LINE-1 methylation level in patients or
controls. Higher methylation levels of NKX2-5 and HAND1 and lower methylation levels of TBX20 were also observed
in patients with TOF than in controls. No association was found between the methylation levels of
NKX2-5, HAND1 and TBX 20 with the LINE-1 methylation level.
Conclusions: Lower LINE-1 methylation levels are associated with increased risk of TOF and may provide important
clues for the development of TOF.
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Tetralogy of fallot (TOF) is a congenital defect caused by
the improper development of the right side of the heart
[1]. TOF accounts for 10% of all congenital heart defects,
with an incidence of 3.6 per 10,000 live births [2]. It is* Correspondence: gyhuang@shmu.edu.cn; duanma@shmu.edu.cn
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reproduction in any medium, provided the orcharacterized by four distinct anatomical features: pul-
monary outflow tract obstruction, ventricular septal
defects (VSD), overriding aortic roots, and right ven-
tricular hypertrophy [3]. TOF malformations can be le-
thal. Although treatment has advanced dramatically over
the past few decades, 0.5% to 6% of TOF patients who
survive after treatment suffer sudden cardiac death [4].
Research into congenital heart disease has come a long
way since the first description and classification of such
conditions. Improvements in utero diagnosis and surgical
techniques have considerably brightened the prospects
of infants born with congenital heart diseases, but truetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of study subjects
Characteristic TOF (n = 32) Control (n = 15)
Age (mean± SD) 19.8 ± 13.9 (months) 13.4 ± 11.0 (years)
Male (%) 22 (68.7) 10 (66.7)
Female (%) 10 (31.3) 5 (33.3)
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have been gained only recently, and their exact etiology
remains unknown [5]. Heredity is likely to play an im-
portant role in the development of TOF [6]. In
recent years, some studies have proved the existence of a
correlation between TOF and gene mutations [4]. NKX2-
5 and HAND1 are known to act as regulatory genes dur-
ing cardiac development. They are evolutionarily inflex-
ible in their regulation of the differentiation of cardiac
muscle cells and morphogenesis of the heart [7,8]. Muta-
tions in NKX2-5 and HAND1 have been identified in
patients with TOF [9]. TBX20, a member of the T-box
transcription factor family, interacts directly with NKX2-
5, GATA4, and GATA5 in the regulation of gene expres-
sion in the developing heart [10]. Mutations and over-ex-
pression of these genes have been identified in patients
with TOF [11]. Some studies have reported chromosomal
abnormalities in infants and fetuses with conotruncal
cardiac malformations [12]. TOF also has a strong asso-
ciation with San Luis Valley Recombinant Chromosome
8 syndrome and trisomy 21 [13]. The causes of TOF are
complex. In addition to disorders in the DNA sequence,
epigenetic regulation has been proven to be associated
with CHD [14]. Despite advances in uncovering the mo-
lecular basis of these epigenetic mechanisms, their roles
in cardiovascular development, tissue homeostasis, and
cardiovascular disease are largely unknown [15]. Altera-
tions of DNA methylation patterns have been found in
many types of cancers, such as lung cancer, brain tumors,
and hepatocellular carcinoma (HCC) [16]. The cancer gen-
ome is frequently characterized by hypermethylation of
specific genes concurrently with an overall decrease in the
level of 5′ methyl cytosine. This hypomethylation of the
global genome promotes chromosomal instability, trans-
location, gene disruption, and reactivation of endoparasitic
sequences [17].
Long interspersed nucleotide element-1 (LINE-1) is a
repetitive element. It constitutes 17–25% of the human
genome [18]. LINE-1 elements are moderately CpG
rich, and most heavily methylated CpGs are located in
the 5′-UTR, where they serve as internal promoters [19].
Because LINE-1 sequences are frequently repeated and
widely interspersed human retrotransposons, their
methylation level can serve as a surrogate marker of glo-
bal genomic DNA methylation [20]. Hypomethylation in
the promoter region of LINE-1 causes transcriptional
activation of LINE-1 element, which causes transposi-
tion of the retroelement and chromosomal alteration
[21]. One recent report has shown that global LINE-1
hypomethylation can repress genome-wide gene expres-
sion [22]. Alterations of LINE-1 methylation status have
been observed frequently in some diseases, such as colon
cancer [23], neural tube defects [24], and systemic lupus
erythematosus [25]. This has been shown to be a goodprognostic marker in certain cancers [26]. Maternal
LINE-1 DNA hypomethylation has been found to be
associated with increased occurrence of non-syndromic
CHDs [20]. LINE-1 showing higher methylation levels
was also observed in Alzheimer’s disease (AD) [27].
These findings suggest that changes in LINE-1 methyla-
tion may not be restricted to cancer but may instead
be present in other diseases and show hypo- or hype-
methylation status under different conditions.
However, it remains unclear whether changes in LINE-
1 methylation are correlated with TOF. Although muta-
tions in NKX2-5, HAND1 and TBX20 have been found
in patients with TOF, together they only account for a
very small percentage of patients [4]. In addition, little
is known about whether changes in methylation are
present in these specific genes.
In the present study, to determine whether alterations
in LINE-1 methylation exist in the TOF tissue sample
and are associated with the risk of TOF, we measured
the methylation level of LINE-1 elements in the TOF
patients and controls and evaluated the association
between LINE-1 methylation status and TOF. The
promoter methylation status of NKX2-5, HAND1 and
TBX20 and their possible association with LINE-1
methylation were also investigated.
Methods
Patients and controls
TOF case subjects were recruited from the Children’s
Hospital of the Fudan University, Shanghai, China. Patients
were diagnosed by echocardiogram, and the diagnoses
were confirmed by surgery. Thirty-two TOF patients
undergoing surgical reconstruction were recruited, includ-
ing 22 (68.8%) male and 10 (31.2%) female patients
ranging in age from 1 to 48 months (mean±SD:
13.4± 11.0 months). The control subjects were recruited
from autopsy specimens at the forensic medicine depart-
ment of the Fudan University, Shanghai, China. Fifteen
healthy control subjects who had died by traffic accidents
were recruited, including 10 (66.7%) males and 5 (33.3%)
females ranging in age from 6 months to 37 years
(mean± SD: 19.8± 13.9 years). All the tissue samples
obtained from right ventricular outflow tracts were saved
in RNAlaterW ( AMBION, Inc., Austin, USA) immediately
after surgical resection or autopsy and stored until use.
This study was approved by the local ethics committee
of the Fudan University. Written informed consent was
Figure 1 Long interspersed nucleotide element-1 (LINE-1). The sequence shown represents a 468 base pair fragment (positions -835–-386) in
the 5′-UTR of LINE-1. Numbers 1–29 refer to locations of the CpG site within the LINE-1 elements tested, and the underlining highlights the CpG
units that include more than one CpG site tested; TSS, transcription star sites.
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jects. Clinical features of the study subjects are summar-
ized in Table 1.DNA extraction and sodium bisulfite conversion
Genomic DNA was extracted from the heart tissue samples
using a QIA amp DNA Mini Kit according to manufac-
turer’s instructions (Qiagen, Hilden, Germany). The con-
centration and purity of the DNA were determined
by absorbance at 260 and 280 nm by NanoDropTM
1000 Spectrophotometer (Thermo Scientific, Wilmington,
USA). Sodium bisulfite modification for the extracted DNA
was performed using an EZ DNA Methylation KitTM
strictly according to manufacturer’s instructions (Zymo
Research, Orange, CA, USA). Sequencing results con-
firmed that more than 99.0% of cytosine residues were
converted. The bisulfite-converted DNA was re-suspended
in 10 μl elution buffer and stored at −80 °C until the
samples were ready for analysis.Table 2 Primer sequences, position, product length, and CpG
analysis





110-mer tag: cagtaatacgactcactatagggagaagg and 2 T7 promoter tag: aggaagagag wQuantitative MassARRAY analysis of gene
methylation status
The Sequenom MassARRAY platform was used to per-
form the quantitative methylation analysis of LINE-1
element. This system, which combines base-specific enzy-
matic cleavage with MALDI-TOF mass spectrometry, is a
highly accurate, sensitive and high-throughput method for
the quantitative analysis of DNA methylation at CpG sites
[28]. The robustness of this approach for quantifying
methylated and unmethylated DNA has been demon-
strated by the Sequenom groups [29]. The region analyzed
and the CpG sites of LINE-1 promoter are shown in
Figure 1. Moreover, the same method was also used for
analysis of the promoter methylation status of NKX 2–5,
HAND1 and TBX20. The primers used in this study
were designed using Methprimer (http://epidesigner.com;
Table 2). For each reverse primer, an additional T7 pro-
moter tag was added for in vivo transcription, and a 10-
mer tag was added to the forward primer to adjust for the
melting temperature differences. Briefly, the 5 μl PCRunits used for MassArray quantitative methylation




AAACCTACAAAAAC −835–-368 468 24
ACCTCTACTCCTC −59–426 486 21
AACAATTCCCAAT −886–-414 473 25
CTAAAAAAACCCT −945–-635 311 17
ere added.
Figure 2 (A) Median methylation levels of long interspersed nucleotide element-1 (LINE1) between control and TOF subjects. (B)
Median methylation levels of 14 informative CpG units in LINE-1 between control and TOF subjects. Control, n = 15; TOF, n = 32. *P <0.05,
**P< 0.01, ***P< 0.001 (Mann–Whitney U test).
Table 3 Association between LINE-1 methylation levels
and risk of TOF
LINE-1
methylation level
TOF (%) Control (%) OR (95% CI) P
(n = 32) (n = 15)
Highest quartile
(>75%)
2 (6.3) 4 (26.7) 1.0 (reference)
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dNTP, 0.2 U of Hot Start TaqDNA polymerase (Seque-
nom, Sequenom Inc., San Diego, CA, U.S.), and a 1 μM
mixture of forward and reverse primers. The PCR mixture
was pre-heated for 4 min at 95 °C and then incubated for
45 cycles of 95 °C for 20 s, 56 °C for 30 s, and 72 °C for
60 s, followed by 72 °C for 3 min. Two microliters of SAP
mix containing 1.7 μlH2O and 0.3 μl (1.7 U) of shrimp al-
kaline phosphatase (Sequenom) was added to digest re-
dundant dNTPs with the following program: 37 °C for
20 min, 85 °C for 5 min, then maintained at 4 °C.
Five microliters of T Cleavage Transcription/RNase
Cocktail, including 0.89 μl 5x T7 polymerase buffer,
0.24 μl T cleavage mix, 3.14 mM dithiothreitol (DDT),
22 U of T7 RNA and DNA Polymerase, 0.09 mg/ml
RNase A, and 2 μl of product of the PCR/SAP reactions
were mixed and incubated under the following conditions:
37 °C for 3 hours of in vitro transcription and RNase A
digestion. Then the mixture was further diluted with H2O
to 27 μl, purified with CLEAN resin (Sequenom) and
robotically dispensed onto silicon chips preloaded with
matrix (SpectroCHIP; Sequenom). The spectra and the
methylation values of matrix-associated laser desorption/
ionization time-of-flight mass spectrometry (Sequenom)
were collected and analyzed using Epityper software (ver-
sion 1.0; Sequenom).
All experiments were performed in triplicate. Inapplic-
able readings and their corresponding sites were elimi-
nated from analysis. The methylation level was expressed
as the percentage of methylated cytosines over the total
number of methylated and unmethylated cytosines.Medium quartile
(25%–75%)
8 (25.0) 8 (53.3) 2.0 (0.3–14.2) 0.65
Lowest quartile
(<25%)
22 (68.7) 3 (20.0) 14.7 (1.8–117.7) 0.014
OR, odds ratio; P, percentile; Cutoffs defined as 25% P and 75% P of the
control group methylation level.Statistical analysis
Data were analyzed using GraphPad Prism (version 5.0;
GraphPad Software Inc., San Diego, CA, U.S.) and SPSS
(version 13.0; SPSS Inc., Chicago, IL, U.S.). Mann–Whitney U test was performed to compare the methyla-
tion levels between the TOF and control groups and be-
tween male and female subjects. The methylation levels
were classified as quartiles according to their distribu-
tions in controls, and the highest quartile was used as
the reference group for risk estimation. Odds ratios
(ORs) and 95% confidence intervals (95% CI) were cal-
culated to estimate the risk of TOF in different methyla-
tion levels using logistic regression. To further explore
whether the hypomethylation of the LINE-1 element
could serve as a prognostic indicator for incidence of
TOF, receiver operator characteristic (ROC) curve ana-
lysis was performed to determine the accuracy in pre-
dicting the presence of TOF. The area under the curve
(AUC) was calculated to evaluate the discriminatory
capacity [30]. T-test was used to compare differences in
age between the TOF and control groups. Chi-square
test was used to compare the differences in gender be-
tween the two groups. Spearman correlation analysis
was performed to evaluate the correlations between the
methylation level of LINE-1 and the methylation levels
of NKX2-5, HAND1 and TBX20 and age. All statistical
analyses were 2-sided and P< 0.05 was considered sta-
tistically significant.
Figure 3 Receiver-operator characteristic (ROC) curve indicating
the discriminatory accuracy in predicting the presence of TOF
by LINE-1 methylation level.
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LINE-1 methylation levels in the TOF patients
and controls
To determine the whole-genome methylation level, we
analyzed the methylation status of the LINE-1 element in
32 patients with TOF and 15 control subjects. To exclude
any tissue heterogeneity that might affect methylation
levels, we used tissue taken from similar regions of the
right ventricular. The amplicon detected in the 5′-UTR of
LINE-1 was 468 base pairs in length and contained 29
CpG sites which could be divided into 24 CpG units. PriorFigure 4 (A) Correlation between LINE-1 methylation level and age into analysis, strict quality control was carried out to re-
move potentially unreliable measurements, such as low
mass, high mass and silent peak overlap CpG units. The
CpG units that failed to produce data for more than 30%
of samples (unreliable CpG units) and samples lacking
more than 30% of their data points (unreliable samples)
were discarded [31]. The methylation level of LINE-1 was
significantly lower in patients with TOF, with a median
value of 57.95% (interquartile range [IQR]: 56.10%–
60.04%), as opposed to 59.70% (IQR: 59.00%–61.30%) in
controls (P=0.0021, Figure 2A).
The methylation level of every CpG unit was also eval-
uated. After the removal of unreliable data, we obtained
14 informative CpG units containing 18 CpG sites.
The mean methylation levels varied across different
CpG units, ranging from 19.8% to 94.3% (Figure 2B).
The methylation levels at CpG_5.6.7, CpG_15, CpG_18.19,
CpG_21, CpG_24, and CpG_26.27 were significantly lower
in patients with TOF than in the controls (P< 0.05). No
significant differences were found at the other CpG units
(P> 0.05).
Association between LINE-1 methylation and the risk
of developing TOF
Twenty-two patients with TOF (68.7%) were grouped
into the lowest quartile (methylation level less than or
equal to 59.0%). Only 2 TOF patients (6.3%) were
grouped into the highest quartile (methylation level
greater than or equal to 61.3%). Eight TOF patients
(25.0%) were categorized into the medium quartile
(methylation level between 59.0% and 61.3%). Subjects in
the lowest quartile had a greater risk of TOF than those
in the highest quartile (OR= 14.7, 95% CI: 1.8–117.7,the control group (n =15) and in the TOF patients (n = 32).
Figure 5 Association between LINE-1 methylation level and gender in (A) control subjects and (B) TOF patients. *P< 0.05, **P< 0.01,
***P< 0.001 (Mann–Whitney U test).
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to have significantly greater risk of TOF than those in
the medium quartile (OR= 2.0, 95% CI: 0.3–14.2,
P= 0.65; Table 3).
ROC curve analysis revealed that the AUC value for
the LINE-1 methylation level was significantly higher in
the TOF patients (AUR= 0.781 for controls vs. TOF
patients, 95%CI: 0.65–0.91, P= 0.002; Figure 3).
Association between of LINE-1methylation and age
No correlation was found between the LINE-1 methylation
and age in the control group (r = 0.11, P=0.67; Figure 4A)
or in TOF patients(r = 0.18, P=0.33; Figure 4B).
Association between of the LINE-1 methylation and gender
No significant difference was found between the median
LINE-1 methylation levels of male and female control
subjects (60.1% vs. 59.3%, P= 0.43; Figure 5A) or in TOF
patients (57.6% vs.58.3%; P= 0.35; Figure 5B). Male TOF
patients had significantly higher median methylation
levels than male controls (60.1% vs.57.6%, P= 0.0057;
Figure 6A). There was no significant difference in the
median LINE-1 methylation level among female subjects
(59.3% vs. 58.3%, P= 0.25; Figure 6B).Figure 6 Association between LINE-1 methylation level and TOF in (A
(Mann–Whitney U test).Association between LINE-1 hypomethylation
and NKX2-5, HAND1, and TBX20 methylation levels
Patients with TOF had significantly higher methylation
levels than controls for both NKX2-5 (30.5% vs. 20.0%,
P= 0.018) and HAND1 (30.5% vs.18.7%, P= 0.0006).
Lower methylation levels of TBX20 were observed
found in the TOF patients than in controls (16.2% vs.
29.5%, P< 0.0001; Table 4). No association was found
between the methylation levels of NKX2-5, HAND1 and
TBX20 and the LINE-1 methylation level (P> 0.05;
Figure 7).Discussion
LINE-1 methylation patterns can serve as an indicator of
global DNA methylation, especially in cancer cell lines
[24]. LINE-1 hypomethylation may have two effects on
the multistep process of carcinogenesis: facilitating
chromosomal instability and controlling gene expression
[22]. However, normal tissues from different organs
showed tissue-specific levels of methylated LINE-1 [32].
In the present study, we demonstrated that the hypo-
methylation levels of LINE-1 were present in the cardiac
tissue of TOF and might increase the risk of developing
TOF. ROC curve analysis confirmed the discriminatory) males and (B) females. *P< 0.05, **P< 0.01, ***P< 0.001
Table 4 Median methylation levels of NKX2-5, HAND1, and TBX20 in the TOF patients and controls
Gene TOF (median, IQR1) Control (median, IQR) P2
HAND1 30.5%, 20.8%–40.9%, n = 30 18.7%, 12.2%–24.8%, n =15 0.0006
TBX20 16.2%, 11.0%–24.1%, n =31 29.5%, 25.0%–38.9%, n =13 <0.0001
NKX2-5 30.5%, 18.4%–43.4%, n =25 20.0%, 13.6%–23.2%, n =13 0.018
1IQR: interquartile range; 2Mann-Whitney U test was used.
Figure 7 Correlations among methylation levels of LINE-1 and (A) NKX2-5 (r = 0.059, P=0.779), (B) HAND1(r =− 0.094, P=0.620),
and (C) TBX20 (r =− 0.183, P=0.323) in the TOF patients samples.
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methylation level, suggesting that hypomethylation of
LINE-1 applicable to the risk assessment of TOF. This
provides initial evidence of the potential pathophysiology
of TOF in pediatric patients. Consistent with one pre-
viously published study on the correlation between
LINE-1 CpGs[33], the methylation status of the CpG
dinucleotides at the LINE-1 promoter regions observed
in this study is not equally distributed. The significant
hypomethylation observed at CpG units may imply
an increase in retro-transposition, which may in turn de-
crease the chromosomal stability of TOF subjects during
early embryonic development. The precise roles of these
factors in the development of chromosomal
instability and retro-transposition require further study.
Changes in epigenetic patterns from one generation to
the next must be evaluated cautiously. These markers
are both cell- and tissue-specific and malleable [34].
Many factors, including age, gender and environmental
factors, have been shown to influence DNA methylation
patterns [31]. Jintaridth et. al studied the relationship
between LINE-1 methylation levels and age and found
that LINE-1 methylation status was not associated with
age in human peripheral blood mononuclear cells [35].
However, age-dependent global DNA demethylation has
also been shown to be associated with many diseases,
such as gastrointestinal cancer [36]. In families with a
history of testicular cancer, researchers have observed
strong gender-specific LINE-1 methylation patterns
between parents and offspring, particularly between
affected fathers and sons [34]. In the present study, we
found no association between LINE-1 methylation and
either age or gender, suggesting that age and gender may
not influence the LINE-1 methylation level. However, we
also found significant association between the LINE-1
methylation status and TOF was present in the male
group but not in the female group. This is consistent
with observations that TOF occurs slightly more often in
men than in women [37].
Genome-wide hypomethylation and hypermethylation at
promoter CpG islands of specific gene are common in can-
cer. Recent studies have shown that genome-wide hypo-
methylation is tightly linked to CpG island
hypermethylation in prostate cancer [38] and neuroendo-
crine tumors [39]. However, global genome hypomethyla-
tion has not been found to be associated with promoter
hypermethylation for specific genes, as assessed in follicu-
lar thyroid cancer [40]. Three genes that regulate heart de-
velopment, NKX2-5, HAND1 and TBX20, play important
roles in the maintenance of normal cardiac development.
Although mutations of NKX2-5, HAND1 and TBX20 have
been found in patients with TOF, they are present only in a
small percentage of patients with congenital heart disease
[4]. Based on these findings, we hypothesized that theepigenetic factors related to these genes, such as DNA
methylation, are likely to contribute to the development of
TOF. In the present study, we found that TOF patients
had significantly higher methylation levels in the promoter
CpG islands of NKX2-5 and HAND1 than controls. They
had lower methylation levels in the promoter CpG island
of TBX20 (Table 4). These changes were consistent with
the reverse results of mRNA expression mircoarray ana-
lysis [41]. However, the question of whether or not these
mRNA-level changes were caused by the altered methyla-
tion status of NKX2-5, HAND1 and TBX20 requires fur-
ther study. We found no correlation between the
methylation status of LINE-1 and that of NKX2-5, HAND1
and TBX20, indicating that the hypomethylation of LINE-1
DNA may not influence the methylation pattern of specific
genes in patients with TOF.
Conclusions
In summary, our results suggest that hypomethylation of
LINE-1 may be associated with increased risk of TOF.
Aberrant methylation of specific genes was observed in
patients with TOF and showed no correlation with the
hypomethylation of LINE-1 DNA. Changes in LINE-1
methylation may be useful epigenetic features for TOF
patients. The difficulty of collecting heart tissue samples
has placed some limitations on this study; we were
unable to obtain enough complete matched samples
from TOF patients and healthy controls. Further studies
with larger sample populations are warranted to confirm
our findings.
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